Business
Ovid Therapeutics Presents Preclinical Data on OV329 at the Epilepsy Foundation Pipeline Conference
OV329 demonstrated robust anti-seizure activity in multiple preclinical seizure and epilepsy models, including treatment-resistant seizuresData demonstrate
About this update from Ovid Therapeutics Inc.
[{"type":"text","content":"OV329 demonstrated robust anti-seizure activity in multiple preclinical seizure and epilepsy models, including treatment-resistant seizuresData demonstrate OV329 has the potential for an improved ocular safety profile and therapeutic index compared to other GABA-aminotransferase (GABA-AT) inhibitors Ovid expects to submit an Investigational New Drug (IND) application in 2H 2022 NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, presented data at the 2022 Epilepsy Foundation Pipeline Conference. New preclinical data support the robust anti-seizure activity of OV329, a next-generation GABA-aminotransferase (GABA-AT) inhibitor in development for rare adult and pediatric epilepsies. “Inhibiting the GABA-AT enzyme has proven to be a highly effective mechanism of action for reducing seizures; yet, safety challenges associated with the currently available medicine in the class significantly limit its use,” said Claude Nicaise, M.D., Head of Research & Development at Ovid. “OV329 is a potential best-in-class GABA-AT inhibitor that could offer patients and families robust seizure reduction without the ocular side effects seen in similar medicines. We plan to advance an IND submission for OV329 to the FDA and expect to initiate clinical studies later this year.” HIGHLIGHTS OF PRECLINICAL FINDINGS Robust anti-seizure activity: Findings from preclinical seizure and epilepsy models indicate that OV329 significantly reduced focal and generalized seizures, including pharmacoresistant seizure phenotypes. Therapeutic dose with enhanced safety margin: A preclinical model of focal seizures (Mesial Temporal Lobe Epilepsies model) in mice demonstrated that repeated administration of OV329 at a dose of 3 mg/kg reduced seizures by approximately 70% by the eighth day of treatment, as compared to placebo. Data presented by Ovid last month at the 2022 EILAT XVI Conference on New Antiepileptic Drugs and Devices found the same dose (3 mg/kg) in rats was well-tolerated with no ocular changes observed following 45 days of repeated exposure, as compared to a generally equivalent human therapeutic dose of vigabatrin (300 mg/kg) which did show ocular toxicity changes at 45 days....